

Biology – Medical Sciences | Technology Offer

Test for the Early Diagnosis of Cerebral Vasospasm


Ensure Technology Leadership through Adoption of this Innovative Breakthrough

At the Heidelberg University, a novel diagnostic procedure was developed which makes it possible to predict whether a patient with a cerebral hemorrhage is likely to suffer a cerebral vasospasm.

State of Current Technology and Market Situation

Cerebral vasospasm is one of the main complications experienced by stroke victims following cerebral hemorrhage. About 30 to 50% of all patients with subarachnoid hemorrhage experience an additional life threatening reduction in blood flow to the brain within the first 7 to 14 days after the stroke. This delay provides theoretically sufficient time to identify and treat therapeutically those likely to suffer such a vasospasm.

Unfortunately currently available methods (angiography, CT, MRI, Doppler sonography and cerebral micro dialysis) only allow diagnosis once a cerebral vasospasm has occurred. An early indicator for vasospasm would therefore be very helpful but does not as yet exist. The novel test presented here, which is based on identifying specific changes in proteins, allows to identify those patients with cerebral hemorrhage that have a substantial risk of also suffering a subsequent cerebral vasospasm.



Pic.: 3D-image demonstrating the expression of the inventive indicator for vasospasm. In comparison with asymptomatic control patients (B) the expression in patients suffering from vasospasm (A) is clearly enhanced.

Innovation

The invention concerns a novel procedure for the early detection of an increased risk of vasospasm by means of molecular indicators.

Your Advantages at a Glance:

The procedure

- Makes it possible to provide prophylactic treatment to patients at risk of vasospasm based on early diagnosis;
- Is simple, quick and low cost; and
- Is unique in that no other early indicator currently exists.

Patent Situation

Patents have already been granted in Germany, in France and in the United Kingdom.

Technology Transfer

The Technologie-Lizenz-Büro GmbH is charged with the commercialisation and now offers companies the opportunity to obtain a licence to exploit this new and promising technology.

For further information, please contact:

Dr. Uta Weirich
uweirich@tlb.de

Technologie-Lizenz-Büro (TLB)
 der Baden-Württembergischen Hochschulen GmbH
 Ettlinger Straße 25, D-76137 Karlsruhe, Germany
 Tel. +49 721 79004-0, Fax +49 721 79004-79

www.tlb.de, our web site, provides information on many other technologies available for licensing.